Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR8 | Q9NR97 | 10/20 | 0.38 |
| ▸ | TLR7 | Q9NYK1 | 4/20 | 0.38 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | USP2 | O75604 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | GBA1 | P04062 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3355146 | 0.84 | MAPT (0.38) | TLR8TLR7MEN1POLBKMT2A | |
| SCHEMBL3351060 | 0.82 | TLR8 (0.44) | TLR8TLR7PRMT5MEN1KMT2A | |
| SCHEMBL2368949 | 0.80 | KDM4E (0.46) | MEN1POLBKMT2ATSHRALDH1A1 | |
| SCHEMBL5618090 | 0.80 | TLR8 (0.39) | TLR8TLR7PRMT5MEN1KMT2A | |
| SCHEMBL5606339 | 0.80 | GBA1 (0.34) | TLR8TLR7MEN1POLBKMT2A | |
| SCHEMBL6053091 | 0.80 | TLR8 (0.38) | TLR8TLR7PRMT5MEN1POLB | |
| SCHEMBL5794472 | 0.78 | PRMT5 (0.40) | TLR8TLR7PRMT5TSHRKDM4E | |
| SCHEMBL191231 | 0.76 | PRMT5 (0.44) | TLR8TLR7PRMT5USP2KDM4E | |
| SCHEMBL2750294 | 0.73 | TLR8 (0.37) | TLR8TLR7PRMT5LMNAHRH4 | |
| SCHEMBL4160702 | 0.69 | PRMT5 (0.42) | TLR8TLR7PRMT5TSHRALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7678918-B2 | Intermediates for imidazonaphthyridines | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2010-03-16 | — | — | US | disclosed |
| US-20080091010-A1 | Intermediates for imidazonaphthyridines | GRACEWAY PHARMACEUTICALS, LLC (US) | 2008-04-17 | — | — | US | disclosed |
| US-7335773-B2 | Intermediates for imidazonaphthyridines | GRACEWAY PHARMACEUTICALS, LLC (US) | 2008-02-26 | — | — | US | disclosed |
| US-20070167481-A1 | IMIDAZONAPHTHYRIDINES | 3M INNOVATIVE PROPERTIES COMPANY | 2007-07-19 | — | — | US | disclosed |
| US-20060128674-A1 | INTERMEDIATES FOR IMIDAZONAPHTHYRIDINES | 3M INNOVATIVE PROPERTIES COMPANY | 2006-06-15 | — | — | US | disclosed |
| US-7038051-B2 | Imidazonaphthyridines | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2006-05-02 | — | — | US | disclosed |
| US-20050288320-A1 | IMIDAZONAPHTHYRIDINES | 3M INNOVATIVE PROPERTIES COMPANY | 2005-12-29 | — | — | US | disclosed |
| US-6949646-B2 | Imidazonaphthyridines | 3M INNOVATIVE PROPERTIES CO. (US) | 2005-09-27 | — | — | US | disclosed |
| US-20050107421-A1 | Imidazonaphthyridines | 3M INNOVATIVE PROPERTIES COMPANY | 2005-05-19 | — | — | US | disclosed |
| US-6894165-B2 | Imidazonaphthyridines | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2005-05-17 | — | — | US | disclosed |
| US-6624172-B2 | Imidazonaphthyridine and tetrahydroimidazonaphthyridine compounds induce the biosynthesis of cytokines such as interferon and tumor necrosis factor, and useful as viricides and antitumor agents | 3M INNOVATIVE PROPERTIES COMPANY | 2003-09-23 | — | — | US | disclosed |
| US-20030096998-A1 | Imidazonaphtyridines | 3M INNOVATIVE PROPERTIES COMPANY | 2003-05-22 | — | — | US | disclosed |
| US-20030083500-A1 | Imidazonaphthyridines | 3M INNOVATIVE PROPERTIES COMPANY | 2003-05-01 | — | — | US | disclosed |
| US-6518280-B2 | Antiviral and antitumor properties; immunomodulators and for inducing cytokine biosynthesis in animals | 3M INNOVATIVE PROPERTIES COMPANY | 2003-02-11 | — | — | US | disclosed |
| US-6514985-B1 | Induce the biosynthesis of cytokines such as interferon and tumor necrosis factor; exhibit antiviral and antitumor properties | 3M INNOVATIVE PROPERTIES COMPANY | 2003-02-04 | — | — | US | disclosed |
| US-20020173654-A1 | Imidazonaphthyridines | 3M INNOVATIVE PROPERTIES COMPANY | 2002-11-21 | — | — | US | disclosed |
| US-20020173653-A1 | Imidazonaphthyridines | 3M INNOVATIVE PROPERTIES COMPANY | 2002-11-21 | — | — | US | disclosed |
| US-6194425-B1 | VIRICIDES, ANTITUMOR AGENTS | 3M INNOVATIVE PROPERTIES COMPANY | 2001-02-27 | — | — | US | disclosed |
| EP-1040112-A1 | IMIDAZONAPHTHYRIDINES AND THEIR USE IN INDUCING CYTOKINE BIOSYNTHESIS | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 2000-10-04 | — | — | EP | disclosed |
| WO-1999029693-A1 | IMIDAZONAPHTHYRIDINES AND THEIR USE IN INDUCING CYTOKINE BIOSYNTHESIS | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1999-06-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080091010-A1 | Intermediates for imidazonaphthyridines | IFNG, IRF3, MAVS | TLR8 182/4885TLR7 135/4885PRMT5 2667/4885 |
| US-20030083500-A1 | Imidazonaphthyridines | IFNG, IRF3, IFNAR1 | TLR8 186/4885TLR7 109/4885PRMT5 2679/4885 |
| US-20030096998-A1 | Imidazonaphtyridines | IFNG, IRF3, IFNAR1 | TLR8 172/4885TLR7 96/4885PRMT5 2679/4885 |
| US-20070167481-A1 | IMIDAZONAPHTHYRIDINES | IFNG, IRF3, IFNAR1 | TLR8 186/4885TLR7 109/4885PRMT5 2679/4885 |
| US-20060128674-A1 | INTERMEDIATES FOR IMIDAZONAPHTHYRIDINES | IFNG, IRF3, MAVS | TLR8 182/4885TLR7 135/4885PRMT5 2667/4885 |
| US-20020173653-A1 | Imidazonaphthyridines | IFNG, IRF3, IFNAR1 | TLR8 186/4885TLR7 109/4885PRMT5 2679/4885 |
| US-20020173654-A1 | Imidazonaphthyridines | IFNG, IRF3, IFNAR1 | TLR8 186/4885TLR7 109/4885PRMT5 2679/4885 |
| US-20050288320-A1 | IMIDAZONAPHTHYRIDINES | IFNG, IRF3, IFNAR1 | TLR8 186/4885TLR7 109/4885PRMT5 2679/4885 |
| US-20050107421-A1 | Imidazonaphthyridines | IFNG, IRF3, IFNAR1 | TLR8 186/4885TLR7 109/4885PRMT5 2679/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.